For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics (ADMA) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adma Biologics is a member of the Medical sector. This group includes 1048 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 1 ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Kristen Kluska - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics First Q ...

Adma Biologics (ADMA) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 60%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of 100%.Over the last four quarte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State o ...

Exhibit 99.1 ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA(1) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increase ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Adma Biologics (ADMA) .Adma Biologics currently has an average brokerage r ...

We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s (ADMA) portfolio of its three marketed commercial products and other pipeline updates when it reports first-quarter 2024 results.Let’s see how things have shaped up for the quarter to be reported.Factors at PlayADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products, ...

tazytaz/E+ via Getty Images Today, we are going to do something different to close out another trading week. In this column, I highlight three biotech stocks with favorable risk/reward profiles and that are trading for under ten bucks a share. Let's start with ADMA Biologics, Inc. (ADMA). This company is focused on manufacturing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. ADMA Biologics recently brought online the last of 10 large plasma collection fa ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

Adma Biologics (ADMA) ended the recent trading session at $6.27, demonstrating a +1.13% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.88%. On the other hand, the Dow registered a gain of 0.56%, and the technology-centric Nasdaq decreased by 2.05%.The the stock of infectious disease drug developer has risen by 0.16% in the past month, leading the Medical sector's loss of 6.4% and the S&P 500's loss of 2.57%.The upcoming earnings release of Ad ...